Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-022647
Filing Date
2022-11-07
Accepted
2022-11-07 16:30:39
Documents
58
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q vrca-20220930.htm   iXBRL 10-Q 2494849
2 EX-31.1 vrca-ex31_1.htm EX-31.1 17828
3 EX-31.2 vrca-ex31_2.htm EX-31.2 18148
4 EX-32.1 vrca-ex32_1.htm EX-32.1 16663
  Complete submission text file 0000950170-22-022647.txt   8006483

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vrca-20220930_lab.xml EX-101.LAB 387240
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vrca-20220930.xsd EX-101.SCH 39716
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT vrca-20220930_def.xml EX-101.DEF 139660
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT vrca-20220930_cal.xml EX-101.CAL 49784
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vrca-20220930_pre.xml EX-101.PRE 265514
52 EXTRACTED XBRL INSTANCE DOCUMENT vrca-20220930_htm.xml XML 1534364
Mailing Address 10 NORTH HIGH STREET SUITE 200 WEST CHESTER PA 19380
Business Address 10 NORTH HIGH STREET SUITE 200 WEST CHESTER PA 19380 484-453-3300
Verrica Pharmaceuticals Inc. (Filer) CIK: 0001660334 (see all company filings)

EIN.: 463137900 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38529 | Film No.: 221365880
SIC: 2834 Pharmaceutical Preparations